Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1997 May;76(3):F179-84.
doi: 10.1136/fn.76.3.f179.

Treatment of patent ductus arteriosus with ibuprofen

B Van Overmeire  1 , I Follens, S Hartmann, W L Creten, K J Van Acker
Affiliations
Clinical Trial

Treatment of patent ductus arteriosus with ibuprofen

B Van Overmeire et al. Arch Dis Child Fetal Neonatal Ed. 1997 May.

Abstract

Aim: To evaluate the efficiency and side effects of ibuprofen for the early treatment of patent ductus arteriosus (PDA) and compare it with indomethacin.

Methods: Forty preterm infants with gestational ages of less than 33 weeks, with respiratory distress syndrome (RDS) and echocardiographically confirmed PDA, were randomly assigned at days 2 to 3 of life to receive either intravenous indomethacin 3 x 0.2 mg/kg at 12 hour intervals or intravenous ibuprofen 1 x 10 mg/kg, followed by 5 mg/kg 24 and 48 hours later.

Results: PDA closed in 15 of 20 patients from the indomethacin group (75%) and in 16 of 20 (80%) from the ibuprofen group. Seven patients (three indomethacin, four ibuprofen) required a second treatment with indomethacin and in five (three in the indomethacin group and two in the ibuprofen group) the duct was ultimately ligated. Ibuprofen patients had a better urinary output and showed no increase in serum creatinine concentrations compared with the indomethacin group. Ibuprofen was not associated with any other side effect.

Conclusions: Ibuprofen treatment seems to be as efficient as indomethacin in closing PDA on the third day of life in preterm infants with respiratory distress syndrome and seems to have fewer renal side effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Urine production in the indomethacin group (upper panel) and the ibuprofen group (lower panel) over 11 days. Day 0 = start of treatment; means ± 1 SE, ± 1 SD. There was a significant difference between the two groups on days 2, 3, and 4 (P=0.002).
Figure 1
Figure 1
Urine production in the indomethacin group (upper panel) and the ibuprofen group (lower panel) over 11 days. Day 0 = start of treatment; means ± 1 SE, ± 1 SD. There was a significant difference between the two groups on days 2, 3, and 4 (P=0.002).
Figure 2
Figure 2
Serum creatinine concentration in the indomethacin group (upper panel) and the ibuprofen group (lower panel) over 11 days. Day 0 = start of treatment; means ± 1 SE ± 1 SD. Maximal difference between the two groups occurred on day 3 (P= 0.07).
Figure 2
Figure 2
Serum creatinine concentration in the indomethacin group (upper panel) and the ibuprofen group (lower panel) over 11 days. Day 0 = start of treatment; means ± 1 SE ± 1 SD. Maximal difference between the two groups occurred on day 3 (P= 0.07).
See this image and copyright information in PMC

Comment in

References

    1. J Appl Physiol (1985). 1993 Apr;74(4):1672-8 - PubMed
    1. J Biol Chem. 1993 Mar 25;268(9):6610-4 - PubMed
    1. J Pediatr. 1995 Nov;127(5):774-9 - PubMed
    1. Pediatr Res. 1995 Dec;38(6):886-91 - PubMed
    1. J Pediatr. 1996 Apr;128(4):470-8 - PubMed

MeSH terms